HUP0402026A3 - 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them - Google Patents

5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them

Info

Publication number: HUP0402026A3
Authority: HU; Hungary
Prior art keywords: diaryl; pyrazine; antagonists; preparation; pharmaceutical compositions
Prior art date: 2001-12-19

Application number

HU0402026A

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-19

Filing date

2002-12-18

Publication date

2005-08-29

2002-12-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-02-28 Publication of HUP0402026A2 publication Critical patent/HUP0402026A2/hu

2005-08-29 Publication of HUP0402026A3 publication Critical patent/HUP0402026A3/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Immunology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HU0402026A 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them HUP0402026A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0104330A SE0104330D0 (sv)	2001-12-19	2001-12-19	Therapeutic agents
PCT/GB2002/005742 WO2003051851A1 (en)	2001-12-19	2002-12-18	5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists

Publications (2)

Publication Number	Publication Date
HUP0402026A2 HUP0402026A2 (hu)	2005-02-28
HUP0402026A3 true HUP0402026A3 (en)	2005-08-29

Family

ID=20286429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0402026A HUP0402026A3 (en)	2001-12-19	2002-12-18	5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them

Country Status (25)

Country	Link
US (1)	US7342019B2 (hu)
EP (1)	EP1458690B1 (hu)
JP (1)	JP2005517655A (hu)
KR (1)	KR20040068286A (hu)
CN (1)	CN1620438A (hu)
AR (1)	AR038044A1 (hu)
AT (1)	ATE354570T1 (hu)
AU (1)	AU2002352425A1 (hu)
BR (1)	BR0214989A (hu)
CA (1)	CA2469786A1 (hu)
CO (1)	CO5590917A2 (hu)
DE (1)	DE60218340T2 (hu)
ES (1)	ES2280599T3 (hu)
HU (1)	HUP0402026A3 (hu)
IL (1)	IL162377A0 (hu)
IS (1)	IS7314A (hu)
MX (1)	MXPA04005990A (hu)
NO (1)	NO20043022L (hu)
NZ (1)	NZ533275A (hu)
PL (1)	PL369731A1 (hu)
RU (1)	RU2004116916A (hu)
SE (1)	SE0104330D0 (hu)
TW (1)	TW200410694A (hu)
WO (1)	WO2003051851A1 (hu)
ZA (1)	ZA200404805B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7704995B2 (en)	2002-05-03	2010-04-27	Exelixis, Inc.	Protein kinase modulators and methods of use
GB0216700D0 (en)	2002-07-18	2002-08-28	Astrazeneca Ab	Process
WO2004029204A2 (en)	2002-09-27	2004-04-08	Merck & Co., Inc.	Substituted pyrimidines
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0302673D0 (en)	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302671D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
GB0314057D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
EP1641779A1 (en) *	2003-06-18	2006-04-05	AstraZeneca AB	2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314049D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314261D0 (en) *	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
EP1644370A4 (en) *	2003-07-11	2008-06-04	Bristol Myers Squibb Co	TETRAHYDROCHINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
US7326706B2 (en) *	2003-08-15	2008-02-05	Bristol-Myers Squibb Company	Pyrazine modulators of cannabinoid receptors
EP1663215A1 (en) *	2003-09-02	2006-06-07	Solvay Pharmaceuticals GmbH	Novel medical use of selective cb1- receptor antagonists
US7320805B2 (en) *	2003-10-01	2008-01-22	Institut National De La Sante Et De La Recherche Medicale	CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
EP1670460B1 (en)	2003-10-10	2014-11-26	Bristol-Myers Squibb Company	Pyrazole derivatives as cannabinoid receptor modulators
AR046132A1 (es) *	2003-10-24	2005-11-23	Solvay Pharm Gmbh	Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
CN1867332A (zh) *	2003-10-24	2006-11-22	索尔瓦药物有限公司	包含选择性cb1－拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗
GB0327331D0 (en) *	2003-11-25	2003-12-31	Astrazeneca Ab	Therapeutic agents
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
TW200602314A (en)	2004-05-28	2006-01-16	Tanabe Seiyaku Co	A novel pyrrolidine compound and a process for preparing the same
AU2005298692A1 (en)	2004-10-25	2006-05-04	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
MX2007012213A (es)	2005-04-06	2007-12-10	Hoffmann La Roche	Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
AU2006236387A1 (en) *	2005-04-18	2006-10-26	Neurogen Corporation	Subtituted heteroaryl CB1 antagonists
KR20080027908A (ko)	2005-06-30	2008-03-28	프로시디온 리미티드	Ｇｐｃｒ 효능제
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en)	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
WO2008040651A1 (en) *	2006-10-04	2008-04-10	F. Hoffmann-La Roche Ag	3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
CL2008000017A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
HRP20110852T1 (hr)	2007-01-04	2011-12-31	Prosidion Limited	PIPERIDINSKI AGONISTI GPCR-a
JP2010514832A (ja)	2007-01-04	2010-05-06	プロシディオン・リミテッド	ピペリジンｇｐｃｒアゴニスト
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
WO2022031946A1 (en)	2020-08-06	2022-02-10	Chdi Foundation, Inc.	Heterobiaryl compounds and imaging agents for imaging huntingtin protein
AR131658A1 (es) *	2023-01-30	2025-04-16	Eurofarma Laboratorios S A	Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
AR131690A1 (es) *	2023-01-30	2025-04-23	Eurofarma Laboratorios S A	COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH458361A (de)	1965-01-15	1968-06-30	Eprova Ag	Verfahren zur Herstellung von Pyrazincarbonsäuren
JPS5322529A (en) *	1976-08-13	1978-03-02	Nippon Soda Co Ltd	Dihydropyrazine derivative and its preparation
EP0397859A4 (en)	1987-11-12	1990-12-19	Terumo Kabushiki Kaisha	Pyrazine derivatives and medicinal preparation containing same
JPH06501926A (ja)	1990-08-06	1994-03-03	藤沢薬品工業株式会社	複素環式化合物
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.

2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
2002
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Withdrawn
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en not_active Ceased
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2004116916A (ru)	2005-11-10
SE0104330D0 (sv)	2001-12-19
ZA200404805B (en)	2005-08-15
DE60218340D1 (de)	2007-04-05
EP1458690A1 (en)	2004-09-22
AU2002352425A1 (en)	2003-06-30
IS7314A (is)	2004-06-16
KR20040068286A (ko)	2004-07-30
AR038044A1 (es)	2004-12-22
ATE354570T1 (de)	2007-03-15
US7342019B2 (en)	2008-03-11
NZ533275A (en)	2006-02-24
CN1620438A (zh)	2005-05-25
CO5590917A2 (es)	2005-12-30
CA2469786A1 (en)	2003-06-26
ES2280599T3 (es)	2007-09-16
BR0214989A (pt)	2004-12-14
MXPA04005990A (es)	2004-09-27
WO2003051851A1 (en)	2003-06-26
IL162377A0 (en)	2005-11-20
PL369731A1 (en)	2005-05-02
TW200410694A (en)	2004-07-01
NO20043022L (no)	2004-07-15
DE60218340T2 (de)	2007-11-29
US20050032808A1 (en)	2005-02-10
EP1458690B1 (en)	2007-02-21
JP2005517655A (ja)	2005-06-16
HUP0402026A2 (hu)	2005-02-28

Publication	Publication Date	Title
HUP0402026A3 (en)	2005-08-29	5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0400989A3 (en)	2011-08-29	Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203836A3 (en)	2005-03-29	1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0402264A3 (en)	2010-03-29	Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HUP0402225A3 (en)	2006-01-30	Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
HUP0300207A3 (en)	2005-07-28	1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes
HUP0301187A3 (en)	2010-03-29	Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401009A3 (en)	2004-10-28	1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
HUP0400246A3 (en)	2009-12-28	1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
HU0103063D0 (en)	2001-10-28	New 2h-pyridazin-3-one derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0400991A3 (en)	2009-06-29	Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them
HUP0303156A3 (en)	2004-03-29	Substituted 2-phenylaminoimidazoline derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0303118A3 (en)	2007-08-28	Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
HUP0402640A3 (en)	2012-09-28	Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions thereof
HUP0401747A3 (en)	2005-06-28	Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0203526A3 (en)	2004-12-28	Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0402282A3 (en)	2007-12-28	Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0204001A3 (en)	2005-04-28	Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401018A3 (en)	2007-05-29	2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
HUP0302515A3 (en)	2005-06-28	Sulfanidothienopyrimidines, process for their preparation and pharmaceutical compositions containing them
HUP0401082A3 (en)	2011-07-28	Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
HUP0303361A3 (en)	2007-03-28	Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202706A3 (en)	2004-12-28	Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists, their intermediates, process for their preparation and pharmaceutical compositions containing them
HUP0401829A3 (en)	2005-06-28	Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- or 4-heteroarylcyclohexane compounds, process for their preparation and pharmaceutical compositions containing the (1h)-quinoxalin-2-one compounds
SI1241169T1 (en)	2003-12-31	Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date	Code	Title	Description
2007-09-28	FD9A	Lapse of provisional protection due to non-payment of fees